Technology transfer programme for influenza vaccines - Lessons from the past to inform the future
- PMID: 35810059
- PMCID: PMC9406834
- DOI: 10.1016/j.vaccine.2022.06.057
Technology transfer programme for influenza vaccines - Lessons from the past to inform the future
Similar articles
-
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30. Hum Vaccin Immunother. 2016. PMID: 26618392 Free PMC article.
-
A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).Vaccine. 2016 Oct 26;34(45):5414-5419. doi: 10.1016/j.vaccine.2016.07.025. Epub 2016 Aug 3. Vaccine. 2016. PMID: 27498212
-
Preparing for a possible pandemic: influenza A/H5N1 vaccine development.Curr Opin Pharmacol. 2007 Oct;7(5):484-90. doi: 10.1016/j.coph.2007.06.004. Epub 2007 Jul 17. Curr Opin Pharmacol. 2007. PMID: 17644429 Review.
-
Designing vaccines for pandemic influenza.Curr Top Microbiol Immunol. 2009;333:165-76. doi: 10.1007/978-3-540-92165-3_8. Curr Top Microbiol Immunol. 2009. PMID: 19768405 Free PMC article. Review.
-
Avian influenza vaccines against H5N1 'bird flu'.Trends Biotechnol. 2014 Mar;32(3):147-56. doi: 10.1016/j.tibtech.2014.01.001. Epub 2014 Feb 1. Trends Biotechnol. 2014. PMID: 24491922 Review.
Cited by
-
'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.PLOS Glob Public Health. 2024 Sep 23;4(9):e0003173. doi: 10.1371/journal.pgph.0003173. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39312552 Free PMC article.
-
Global production capacity of seasonal and pandemic influenza vaccines in 2023.Vaccine. 2025 Apr 2;51:126839. doi: 10.1016/j.vaccine.2025.126839. Epub 2025 Feb 18. Vaccine. 2025. PMID: 39970592 Free PMC article.
-
Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries.PLOS Glob Public Health. 2024 Jul 1;4(7):e0003418. doi: 10.1371/journal.pgph.0003418. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38950021 Free PMC article. Review.
-
Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond.Pharmaceut Med. 2023 May;37(3):203-214. doi: 10.1007/s40290-023-00473-z. Epub 2023 Apr 28. Pharmaceut Med. 2023. PMID: 37115494 Free PMC article.
References
-
- Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine. 2011;29 Suppl 1:A2-7. - PubMed
-
- World Health Organization. Report of the third WHO consultation on the Global Action Plan for Influenza Vaccines: Geneva, Switzerland, 15-16 November 2016. Geneva: World Health Organization; 2017.
-
- Hendriks J., Holleman M., de Boer O., de Jong P., Luytjes W. An international technology platform for influenza vaccines. Vaccine. 2011;29(Suppl 1):A8–A11. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous